Gilead Sciences (GILD) Non-Current Deferred Tax Liability (2020 - 2026)
Gilead Sciences filings provide 10 years of Non-Current Deferred Tax Liability readings, the most recent being $402.0 million for Q4 2025.
- On a quarterly basis, Non-Current Deferred Tax Liability fell 44.48% to $402.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $402.0 million, a 44.48% decrease, with the full-year FY2025 number at $402.0 million, down 44.48% from a year prior.
- Non-Current Deferred Tax Liability hit $402.0 million in Q4 2025 for Gilead Sciences, down from $597.0 million in the prior quarter.
- In the past five years, Non-Current Deferred Tax Liability ranged from a high of $6.1 billion in Q4 2022 to a low of $402.0 million in Q4 2025.
- Median Non-Current Deferred Tax Liability over the past 5 years was $2.0 billion (2023), compared with a mean of $2.4 billion.
- Biggest five-year swings in Non-Current Deferred Tax Liability: skyrocketed 40.54% in 2022 and later tumbled 74.06% in 2023.
- Gilead Sciences' Non-Current Deferred Tax Liability stood at $4.4 billion in 2021, then surged by 40.54% to $6.1 billion in 2022, then tumbled by 74.06% to $1.6 billion in 2023, then plummeted by 54.41% to $724.0 million in 2024, then plummeted by 44.48% to $402.0 million in 2025.
- The last three reported values for Non-Current Deferred Tax Liability were $402.0 million (Q4 2025), $597.0 million (Q3 2025), and $652.0 million (Q2 2025) per Business Quant data.